What is Regorafenib?

Regorafenib (Regorafenib) is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have previously received span>Possiblyfluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and antiEGFR therapy is also indicated for the treatment of patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Regofenibis also suitable for the treatment of patients with hepatocellular carcinoma (HCC) who have previously received sorafenib.

Regofenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and pathological processes, such as tumorigenesis, tumor angiogenesis, and maintenance of the tumor microenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and M-5 inhibit the activity of RET, VEGFR1, VEGFR2, VEGFR3, etc. at clinically achieved concentrations of regorafenib.

RegofenibThe original drug has been launched in China and has entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. SpecificationThe price of each box of 40mg*28 tablets is around RMB 5,000. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The Turkish version of regorafeniboriginal drug specifications 40mg*28 tablets sold overseas is priced around RMB 6,400 per box (the price may fluctuate due to exchange rates). There are also generic regorafenib drugs produced in other countries, and their drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*90 tablets produced by a Bangladesh pharmaceutical factory is around 2,900 yuan (the price may fluctuate due to exchange rates).